I-Mab Presents Positive Givastomig Phase 1b Data at ESMO GI
Ticker: NBP · Form: 6-K · Filed: Jul 2, 2025 · CIK: 1778016
Sentiment: bullish
Topics: clinical-trial-data, oncology, drug-development
TL;DR
I-Mab's Givastomig shows promise in early-stage gastric cancer trials, positive data released July 2nd.
AI Summary
I-Mab announced on July 2, 2025, positive Phase 1b dose escalation data for its drug Givastomig. The data, presented at ESMO GI, shows Givastomig in combination with immunochemotherapy in patients with first-line (1L) advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Why It Matters
Positive clinical trial data for Givastomig could lead to its approval and wider use, potentially improving treatment outcomes for patients with advanced gastric and GEJ cancers.
Risk Assessment
Risk Level: medium — Clinical trial results are preliminary and subject to further validation and regulatory approval, with inherent risks in drug development.
Key Players & Entities
- I-Mab (company) — Registrant and developer of Givastomig
- Givastomig (drug) — Drug candidate being studied
- ESMO GI (conference) — Venue for data presentation
- July 2, 2025 (date) — Date of data presentation and filing
FAQ
What specific type of cancer does the Givastomig Phase 1b data focus on?
The data focuses on patients with first-line (1L) advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
What was the combination therapy tested with Givastomig?
Givastomig was tested in combination with immunochemotherapy.
Where was this Phase 1b data presented?
The data was presented at the ESMO GI conference.
What is the form type filed by I-Mab?
I-Mab filed a Form 6-K.
What is the filing date of this report?
The filing date is July 2, 2025.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on July 2, 2025 regarding I-Mab (NBP).